STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
RGEN REPLIGEN CORPORATION StockScouter® Report
3
StockScouter® Score
REPLIGEN CORPORATION, a mid cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with slightly less than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- One or more analysts has significantly increased quarterly earnings estimates for RGEN. Positive
Concerns
- The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
- Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative
- The ratio of RGEN’s forward price-to-earnings multiple to its estimated growth rate is well above the average of comparably-sized companies in the StockScouter universe. Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be out of favor, growth stocks will be out of favor, and healthcare stocks will be out of favor.
Expected Risk/Return
Core Model Grades
B
D
F
B